Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Azad

Showing results (351-360 of 353) with videos related to

Pageof 36
Sort By:
You have reached the last page of results.This site can display upto 353 results.
Lancet (London, England)|February 14, 2021
[<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Cancer Discovery|July 2, 2026
Germline CDK12 variants in aggressive prostate cancerSofie H Tolmeijer, Corinne Maurice-Dror, Shahneen Sandhu, et al.
Nature Communications|August 20, 2021
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncologyGail P Risbridger, Ashlee K Clark, Laura H Porter, et al.
Pageof 36

Showing results (351-360 of 353) with videos related to

Sort By:
Pageof 36
You have reached the last page of results.This site can display upto 353 results.
Lancet (London, England)|February 14, 2021
[<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
Cancer Discovery|July 2, 2026
Germline CDK12 variants in aggressive prostate cancerSofie H Tolmeijer, Corinne Maurice-Dror, Shahneen Sandhu, et al.
Nature Communications|August 20, 2021
The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncologyGail P Risbridger, Ashlee K Clark, Laura H Porter, et al.
Pageof 36